Atara Biotherapeutics (NASDAQ:ATRA) Posts Earnings Results, Beats Expectations By $0.84 EPS

Atara Biotherapeutics (NASDAQ:ATRA) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($2.93) EPS for the quarter, topping the consensus estimate of ($3.77) by $0.84, Zacks reports. The company had revenue of $40.19 million during the quarter, compared to analyst estimates of $23.00 million. During the same quarter in the prior year, the company posted ($16.50) earnings per share.

Atara Biotherapeutics Stock Up 22.2 %

NASDAQ ATRA opened at $14.26 on Thursday. Atara Biotherapeutics has a 52 week low of $6.48 and a 52 week high of $39.50. The firm has a 50 day moving average of $8.89 and a two-hundred day moving average of $10.30. The stock has a market capitalization of $70.02 million, a PE ratio of -0.55 and a beta of 0.50.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Mizuho raised shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and lowered their price objective for the company from $25.00 to $18.00 in a research note on Friday, August 16th. HC Wainwright reissued a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st. The Goldman Sachs Group cut their price objective on Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating on the stock in a research report on Wednesday, July 17th. Finally, Canaccord Genuity Group increased their price objective on Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $16.67.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.